•  
  •  
  •  
  •  

2026-05-23 21:42:59

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores

Keywords Selected:  Semaglutide

Stock Report

  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • OneSource Supports Second Generic Semaglutide Approval in Canada
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
  • Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India
  • Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India
  • Eris Lifesciences Ltd to launch Weekly Shot of Semaglutide Starting at ₹220 Per Shot
  • NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290
  • Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India
  • Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India
  • Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry
  • Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India
  • OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic® in Saudi Arabia
  • Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries
  • Biocon Ltd signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic

Latest Post

  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025